Please log in to view this page
Username
Password
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
